Monod Bio, Inc.
- Diagnostics
- Medical device or technology
- Other products or services
- Synthesis, analytic, diagnostic services
Monod Bio, co-founded in 2022 by Nobel laureate David Baker, leverages pioneering AI-based protein design technology to develop breakthrough diagnostic reagents and life science tools. Our "Monod Inside" model enables partners to develop and commercialize differentiated products based on the NovoBody™ (superior alternatives to antibodies), NovoBody Duo™ (multi-specific binding proteins), LuxSit™ (de novo luciferases), and NovoLISA™ (one-step homogeneous ELISA) platforms. We empower leading diagnostic assay developers and life science tools providers to rapidly bring superior products to market and address the most pressing challenges faced by their customers.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}